Sobi Pays $75M to Advance Innate’s Lacutamab in Cutaneous T-Cell Lymphoma
Event summary
- Sobi and Innate’s partnership is now effective, clearing antitrust hurdles.
- Sobi pays Innate $75M upfront, with up to $580M in potential milestone payments.
- TELLOMAK-3 Phase 3 trial for lacutamab in Sézary syndrome to begin Q1 2027.
- Sobi gains exclusive global commercialization rights upon accelerated approval.
- Innate eligible for double-digit royalties on net sales.
The big picture
This deal underscores Sobi’s push into rare disease therapies, while Innate gains financial stability to advance its pipeline. The $75M upfront payment and potential $580M in milestones highlight the high stakes in securing accelerated approval for lacutamab, a critical step for both companies in a niche but growing oncology segment.
What we're watching
- Regulatory Timing
- Whether the TELLOMAK-3 trial delivers data quickly enough to support an accelerated approval filing in 2027.
- Commercial Potential
- How Sobi positions lacutamab in the competitive landscape of cutaneous T-cell lymphoma treatments.
- Financial Upside
- The pace at which Innate could unlock the remaining $580M in milestone payments and royalties.
Related topics